H. Stass

发表

Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.

G. Wensing, K. Breithaupt-Grögler, C. Malerczyk, 1997, International journal of clinical pharmacology and therapeutics.

A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life

T. Eissing, U. Jaehde, H. Stass, 2018, Clinical Pharmacokinetics.

Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study

Stefan Willmann, H. Stass, S. Willmann, 2013, Clinical Drug Investigation.

Defining the Role of Macrophages in Local Moxifloxacin Tissue Concentrations using Biopsy Data and Whole-Body Physiologically Based Pharmacokinetic Modelling

Stefan Willmann, Andrea N Edginton, H. Stass, 2009, Clinical pharmacokinetics.

Capillary electrophoresis with laser-induced fluorescence: a routine method to determine moxifloxacin in human body fluids in very small sample volumes.

R. Heinig, H. Stass, G. Blaschke, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Once-Daily Treatment Using Ciprofloxacin in an Extended-Release Dosage Form*

E. Schuck, H. Derendorf, H. Stass, 2005, Infection.

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease

J. Altcheh, F. Garcia-Bournissen, H. Stass, 2020, Clinical pharmacology in drug development.

Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species.

C. Kohlsdorfer, H. Stass, H. Siefert, 1999, The Journal of antimicrobial chemotherapy.

Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers.

H. Stass, J. Nagelschmitz, Boris Weimann, 2017, Journal of aerosol medicine and pulmonary drug delivery.

Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease

E. Minar, N. Klein, M. Müller, 2001, Clinical pharmacology and therapeutics.

Pharmacokinetics, Safety, and Tolerability of Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy Subjects

H. Stass, D. Kubitza, A. Dalhoff, 1998, Antimicrobial Agents and Chemotherapy.

Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis.

A. Patzlaff, H. Stass, J. Nagelschmitz, 2019, Journal of aerosol medicine and pulmonary drug delivery.

Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.

H. Stass, D. Staab, J. Nagelschmitz, 2015, Journal of aerosol medicine and pulmonary drug delivery.

Pharmacokinetics, Safety and Tolerability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, after Repeated Oral Administration

H. Stass, D. Kubitza, U. Schühly, 2001, Clinical Pharmacokinetics.

Penetration of Moxifloxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in Humans

E. Minar, H. Stass, Markus Müller, 2003, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of Moxifloxacin and Levofloxacin Simulating Human Serum and Lung Concentrations*

H. Stass, U. Ullmann, S. Schubert, 2005, Infection.

Pharmacokinetics and Tissue Penetration of Moxifloxacin in Intervention Therapy for Intra-Abdominal Abscess

H. Stass, D. Kubitza, H. Delesen, 2008, Clinical drug investigation.

Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas Disease

H. Stass, S. Willmann, I. Ince, 2022, Journal of clinical pharmacology.

The Integrated Use of Pharmacokinetic and Pharmacodynamic Models for the Definition of Breakpoints

H. Stass, A. Dalhoff, 2005, Infection.

Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis.

H. Stass, D. Kubitza, H. Delesen, 2006, The Journal of antimicrobial chemotherapy.

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A

H. Stass, A. Luk, E. Gorina, 2008 .

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.

H. Stass, A. Luk, E. Gorina, 2008, Journal of thrombosis and haemostasis : JTH.

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin

T. Eissing, J. Lippert, H. Stass, 2019, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study

H. Stass, J. Lettieri, S. Willmann, 2019, Journal of clinical pharmacology.

Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII – an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia

H. Stass, 2006 .

Stability, efficacy, and safety of continuously infused sucrose‐formulated recombinant factor VIII (rFVIII‐FS) during surgery in patients with severe haemophilia

H. Stass, A. Lubetsky, B. Ravid, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics of Moxifloxacin in Special Populations

H. Stass, J. Lettieri, 1999, Drugs.

Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction.

H. Stass, A. Halabi, D. Kubitza, 2002, British journal of clinical pharmacology.

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.

H. Stass, D. Kubitza, 1999, The Journal of antimicrobial chemotherapy.

Evaluation of the Influence of Antacids and H2 Antagonists on the Absorption of Moxifloxacin after Oral Administration of a 400mg Dose to Healthy Volunteers

K. Ochmann, H. Stass, M. Böttcher, 2001, Clinical Pharmacokinetics.

Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects.

H. Stass, J. Nagelschmitz, H. Delesen, 2004, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease.

H. Stass, M. Eldon, K. Corkery, 2011, Journal of aerosol medicine and pulmonary drug delivery.

Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing.

H. Stass, A. Dalhoff, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Penetration of Moxifloxacin into Peripheral Compartments in Humans

H. Eichler, M. Brunner, H. Stass, 1999, Antimicrobial Agents and Chemotherapy.

Moxifloxacin does not Alter Ciclosporin Pharmacokinetics in Transplant Patients

I. Roots, H. Stass, D. Kubitza, 2012 .

Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study.

I. Roots, H. Stass, D. Kubitza, 2010, Clinical drug investigation.

Penetration and accumulation of moxifloxacin in uterine tissue

B. Aydeniz, C. Gleiter, H. Stass, 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction.

A. Kribben, A. Mitchell, H. Stass, 2007, British Journal of Clinical Pharmacology.

A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus.

J. Pagès, H. Stass, P. Arvis, 2002, The Journal of antimicrobial chemotherapy.

Capillary electrophoresis with laser-induced fluorescence detection, an adequate alternative to high-performance liquid chromatography, for the determination of ciprofloxacin and its metabolite desethyleneciprofloxacin in human plasma.

H. Stass, G. Blaschke, K. H. Bannefeld, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis.

A. Gous, J. Scribante, H. Stass, 2005, International journal of antimicrobial agents.

Single- and Multiple-dose Pharmacokinetics of Oral Moxifloxacin and Clarithromycin, and Concentrations in Serum, Saliva and Faeces

H. Lode, H. Stass, C. Nord, 2002, Scandinavian journal of infectious diseases.

Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?

J. Scribante, H. Stass, J. Lipman, 2002, Intensive Care Medicine.

Metabolism and Excretion of Moxifloxacin

H. Stass, 1999, Drugs.

Effects of Dairy Products on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers

H. Stass, D. Kubitza, 2001, Clinical Pharmacokinetics.

Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers

H. Stass, J. Möller, H. Delesen, 2001, Clinical Pharmacokinetics.

Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects

H. Stass, S. Specht, J. Gillon, 2021, British journal of clinical pharmacology.

Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients

U. Schaad, J. Kuhlmann, H. Stass, 1996, Antimicrobial agents and chemotherapy.

Determination of the Concentration of Ciprofloxacin in Prostate Tissue Following Administration of a Single, 1000 mg, Extended-Release Dose

H. Stass, J. Lettieri, J. Lugg, 2008, Journal of chemotherapy.

Determination of moxifloxacin anaerobic susceptibility breakpoints according to the Clinical and Laboratory Standards Institute guidelines.

J. Ambler, L. Koeth, R. Rennie, 2008, Diagnostic microbiology and infectious disease.

Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox

H. Stass, Isabel Piel, D. Lang, 2022, Chemical research in toxicology.

Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding

H. Stass, S. Willmann, Boris Weimann, 2022, The AAPS Journal.

Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.

H. Stass, J. Möller, D. Kubitza, 2005, British journal of clinical pharmacology.

Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin

Alan Forrest, Jerome J. Schentag, H. Stass, 2004, Antimicrobial Agents and Chemotherapy.

Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study

S. Emil, H. Stass, S. Willmann, 2018, The Pediatric infectious disease journal.

Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.

H. Stass, D. Staab, C. Rolinck-Werninghaus, 2013, Clinical therapeutics.

Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.

H. Stass, J. Chastre, C. Luyt, 2011, Journal of aerosol medicine and pulmonary drug delivery.

Urinary Excretion and Bactericidal Activity of Intravenous Ciprofloxacin Compared with Oral Ciprofloxacin

H. Stass, U. Theuretzbacher, K. Naber, 1999, European Journal of Clinical Microbiology and Infectious Diseases.

Profile of moxifloxacin drug interactions.

H. Stass, D. Kubitza, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock

T. Welte, Mathias W Pletz, F. Brunkhorst, 2010, Intensive Care Medicine.

926: RISK ASSESSMENT FOR AMIKACIN INHALE IN ICU PATIENTS USING WHOLE-BODY PHYSIOLOGICALLY-BASED PK-MODELS

H. Stass, S. Willmann, T. Wendl, 2013 .

Lack of Pharmacokinetic Interaction between Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, and Theophylline

H. Stass, D. Kubitza, 2001, Clinical Pharmacokinetics.

Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets - implications for quality control and application.

H. Stass, S. Willmann, S. Just, 2021, European Journal of Pharmaceutical Sciences.

Absolute bioavailability of moxifloxacin.

H. Stass, J. T. Sullivan, J. Lettieri, 1999, Clinical therapeutics.

Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.

H. Stass, J. Nagelschmitz, H. Delesen, 2015, Journal of aerosol medicine and pulmonary drug delivery.

Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.

H. Stass, D. Staab, J. Nagelschmitz, 2013, Clinical therapeutics.

Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder

H. Stass, S. Willmann, D. Staab, 2008 .

Effects of Iron Supplements on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Humans

H. Stass, D. Kubitza, 2001, Clinical Pharmacokinetics.